Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China · Delayed Price · Currency is CNY 15.70
+0.12 (0.77%)
Sep 8, 2025, 2:45 PM CST
Yifan Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 436.39 | 385.97 | -551.07 | 191.22 | 278.4 | 968.39 | Upgrade |
Depreciation & Amortization | 341.71 | 331.44 | 270.6 | 228.43 | 207.18 | 177.01 | Upgrade |
Other Amortization | 81.44 | 76.37 | 29.06 | 9.48 | 6.88 | 9.43 | Upgrade |
Loss (Gain) From Sale of Assets | -31.81 | -30.15 | -2.57 | 0.56 | -14.83 | 0.04 | Upgrade |
Asset Writedown & Restructuring Costs | 14.9 | 11.48 | 852.61 | 102.13 | 38.25 | 6.6 | Upgrade |
Loss (Gain) From Sale of Investments | 27.25 | 14.16 | 15.06 | 17.63 | 4.49 | -6.95 | Upgrade |
Provision & Write-off of Bad Debts | 9.19 | 61.63 | 60.47 | 29.12 | 21.34 | 8.19 | Upgrade |
Other Operating Activities | 50.25 | 37 | -237.89 | 38.44 | 56.52 | 40.34 | Upgrade |
Change in Accounts Receivable | -148.74 | -363.72 | -10.25 | -103.77 | -18.59 | -117.71 | Upgrade |
Change in Inventory | -139.15 | -147.75 | -109.39 | -167.1 | -80.48 | 21.86 | Upgrade |
Change in Accounts Payable | 107.72 | 239.99 | 62.88 | 156.63 | -99.34 | -49.22 | Upgrade |
Change in Other Net Operating Assets | 47.96 | 19.71 | 21.79 | 23.15 | -10.3 | 82.7 | Upgrade |
Operating Cash Flow | 783.05 | 640.73 | 348.58 | 472.07 | 301.23 | 1,109 | Upgrade |
Operating Cash Flow Growth | 131.04% | 83.81% | -26.16% | 56.71% | -72.82% | 18.27% | Upgrade |
Capital Expenditures | -619.98 | -628.16 | -504.09 | -542.27 | -571.74 | -715.71 | Upgrade |
Sale of Property, Plant & Equipment | 7.26 | 0.32 | 5.02 | 7.84 | 17.7 | 0.96 | Upgrade |
Cash Acquisitions | - | - | - | - | -42 | -39.81 | Upgrade |
Divestitures | - | 5.29 | 1.06 | 1.2 | 15.9 | 3 | Upgrade |
Investment in Securities | 101.16 | 75 | -39.13 | -137.58 | 66.6 | -26 | Upgrade |
Other Investing Activities | 3.11 | 2.67 | 4.3 | 0.65 | 5.64 | 7.01 | Upgrade |
Investing Cash Flow | -508.45 | -544.88 | -532.84 | -670.17 | -507.89 | -770.55 | Upgrade |
Long-Term Debt Issued | - | 2,001 | 1,855 | 1,789 | 2,928 | 1,957 | Upgrade |
Long-Term Debt Repaid | - | -1,709 | -2,044 | -1,897 | -2,448 | -2,210 | Upgrade |
Net Debt Issued (Repaid) | 72.1 | 291.87 | -189.38 | -107.72 | 480.27 | -252.97 | Upgrade |
Issuance of Common Stock | - | - | - | 0.85 | 1 | - | Upgrade |
Repurchase of Common Stock | - | - | -38 | -53.56 | -121.47 | -1.62 | Upgrade |
Common Dividends Paid | -310.28 | -194.81 | -72.47 | -86.38 | -138.39 | -201.98 | Upgrade |
Other Financing Activities | -4.29 | 15.67 | 330.62 | 234.15 | 0.75 | -111.38 | Upgrade |
Financing Cash Flow | -242.47 | 112.73 | 30.78 | -12.66 | 222.16 | -567.95 | Upgrade |
Foreign Exchange Rate Adjustments | 12.71 | -3.69 | 14.59 | 59.56 | -20.85 | 1.33 | Upgrade |
Net Cash Flow | 44.84 | 204.89 | -138.88 | -151.2 | -5.36 | -228.66 | Upgrade |
Free Cash Flow | 163.08 | 12.57 | -155.5 | -70.21 | -270.51 | 392.8 | Upgrade |
Free Cash Flow Growth | - | - | - | - | - | 451.93% | Upgrade |
Free Cash Flow Margin | 3.16% | 0.24% | -3.82% | -1.83% | -6.13% | 7.27% | Upgrade |
Free Cash Flow Per Share | 0.14 | 0.01 | -0.13 | -0.06 | -0.22 | 0.32 | Upgrade |
Cash Income Tax Paid | 298.47 | 321.69 | 362.22 | 91.5 | 220.66 | 456.31 | Upgrade |
Levered Free Cash Flow | -14.23 | -171.28 | -160.61 | -347 | -430.33 | -173.92 | Upgrade |
Unlevered Free Cash Flow | 24.19 | -128.1 | -113.39 | -293.35 | -383.71 | -129.5 | Upgrade |
Change in Working Capital | -146.26 | -247.18 | -87.68 | -144.96 | -295.73 | -95.8 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.